To the Editor: In the CARD trial reported by de Wit et al. (Dec. 26 issue),(1) 255 patients with metastatic castration-resistant prostate cancer who had previously received docetaxel and who had disease progression while receiving abiraterone or enzalutamide were randomly assigned to cabazitaxel or the other androgen-signaling-targeted inhibitor. Cabazitaxel significantly improved several clinical outcomes, including imaging-based progression-free survival and overall survival, as compared with hormonal treatment. This trial represents an important step forward in the understanding of appropriate advanced treatment in patients with metastatic castration-resistant prostate cancer. However, it should be noted that 61.2% of the patients received hormonal treatment . . .
Di Nunno V., Mollica V., Massari F., De Wit R., De Bono J., Castellano D. (2020). Cabazitaxel in metastatic prostate cancer. THE NEW ENGLAND JOURNAL OF MEDICINE, 382(13), 1286-1286 [10.1056/NEJMc2000990].
Cabazitaxel in metastatic prostate cancer
Di Nunno V.;Mollica V.;Massari F.;
2020
Abstract
To the Editor: In the CARD trial reported by de Wit et al. (Dec. 26 issue),(1) 255 patients with metastatic castration-resistant prostate cancer who had previously received docetaxel and who had disease progression while receiving abiraterone or enzalutamide were randomly assigned to cabazitaxel or the other androgen-signaling-targeted inhibitor. Cabazitaxel significantly improved several clinical outcomes, including imaging-based progression-free survival and overall survival, as compared with hormonal treatment. This trial represents an important step forward in the understanding of appropriate advanced treatment in patients with metastatic castration-resistant prostate cancer. However, it should be noted that 61.2% of the patients received hormonal treatment . . .I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
